SCHEMBL1665342

SCHEMBL1665342

CC(OC(=O)C1CCCCC1C(=O)OC(C)c1ccccc1)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.49
TAAR1 Q96RJ0 1/20 0.47
KCNQ3 O43525 1/20 0.47
KCNQ2 O43526 1/20 0.47
TSHR P16473 2/20 0.43
LMNA P02545 4/20 0.43
EPHX1 P07099 2/20 0.43
CYP3A4 P08684 2/20 0.43
HPGD P15428 1/20 0.43
CYP2C19 P33261 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
RECQL P46063 1/20 0.43
CYP1A2 P05177 2/20 0.42
CYP2D6 P10635 2/20 0.42
MAPK1 P28482 1/20 0.42
HSD17B10 Q99714 1/20 0.42
SLC6A2 P23975 1/20 0.41
SLC6A4 P31645 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1665343 0.95 TAAR1 (0.53) HCAR2TAAR1KCNQ3KCNQ2TSHR
SCHEMBL2034468 0.86 HCAR2 (0.45) HCAR2TSHRLMNAEPHX1CYP3A4
SCHEMBL1665337 0.85 CHRM2 (0.44) TAAR1TSHRLMNACYP3A4HPGD
SCHEMBL22791138 0.85 LMNA (0.58) HCAR2TSHRLMNAEPHX1HPGD
SCHEMBL3863050 0.84 SMN1; SMN2 (0.42) TSHRCYP3A4HPGDCYP2C19RAB9A
SCHEMBL3863047 0.84 SMN1; SMN2 (0.42) TSHRCYP3A4HPGDCYP2C19RAB9A
SCHEMBL1667289 0.84 HCAR2 (0.41) HCAR2TAAR1KCNQ3KCNQ2TSHR
SCHEMBL1664723 0.83 HCAR2 (0.49) HCAR2TAAR1TSHRLMNACYP3A4
SCHEMBL1667292 0.83 HCAR2 (0.40) HCAR2TAAR1KCNQ3KCNQ2TSHR
SCHEMBL27904989 0.83 HCAR2 (0.51) HCAR2TSHRLMNACYP3A4RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011071674-A1 ASYMMETRIC CYCLIC DIESTER COMPOUNDS FERRO CORPORATION (US) 2011-06-16 WO disclosed
EP-2307476-A1 ASYMMETRIC CYCLIC DIESTER COMPOUNDS FERRO CORPORATION (US) 2011-04-13 EP disclosed
US-20100113664-A1 Asymmetric Cyclic Diester Compounds FERRO CORPORATION (US) 2010-05-06 US disclosed
WO-2009152068-A1 ASYMMETRIC CYCLIC DIESTER COMPOUNDS FERRO CORPORATION (US) 2009-12-17 WO disclosed
US-20090312470-A1 Asymmetric Cyclic Diester Compounds FERRO CORPORATION (US) 2009-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312470-A1 Asymmetric Cyclic Diester Compounds DDT, PCNA, AADAC HCAR2 1123/4885TAAR1 2173/4885KCNQ3 3305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.